Introduction
Mammalian cells lack the autonomous ability to utilize the nutrients in their environment. The cellular uptake and metabolism of nutrients is controlled by the availability of extracellular signals, in the form of hormones, cytokines, and growth factors (Hedeskov, 1968; Whetton et al., 1985; Berridge and Tan, 1995) . Cells also rely on such extracellular signals to drive cell growth, proliferation, and survival (Conlon and Raff, 1999) . We have utilized hematopoietic cells as a model to understand how cell-extrinsic factors coordinate metabolism, growth, and survival. One surprising feature of cytokine signaling in nontransformed hematopoietic cells is that it directly stimulates glucose metabolism in excess of these cells' bioenergetic demands and independent of cell growth and survival .
In contrast to nontransformed cells, most cancer cells have the autonomous ability to utilize nutrients (Dang and Semenza, 1999) . They accomplish this self-sufficiency by the constitutive activation of the same growth factor signaling pathways that link receptor engagement to nutrient utilization in normal cells (Elstrom et al., 2004) . The PI3K/Akt signaling pathway is a critical mediator of cytokine-stimulated glucose metabolism in hematopoietic cells Bentley et al., 2003) . Akt was originally identified as a potent oncogene, and constitutive PI3K/Akt activation is commonly observed in cancer cells (Bellacosa et al., 1991; Vivanco and Sawyers, 2002; Franke et al., 2003; Luo et al., 2003) . PI3K/Akt signaling is sufficient to stimulate glucose uptake and glycolysis in a variety of cell types (Kohn et al., 1996; Deprez et al., 1997; Plas et al., 2001) .
We hypothesized that the primary regulation of glucose metabolism by growth factor signal transduction may allow cells to engage in a form of metabolism that supports cell growth. Glucose has at least two possible fates within a cell: it may be oxidized to produce cellular bioenergy; and it may be converted into other macromolecules to support cellular biosynthesis. Extracellular signals may directly upregulate glucose utilization to induce sufficient metabolism to both meet bioenergetic demands and stimulate glucose-dependent macromolecular synthesis.
One of the biosynthetic fates of glucose is the conversion to lipid that occurs during de novo lipogenesis ( Figure 1a ). The carbons of glucose, after being converted to pyruvate by cellular glycolysis, imported into mitochondria, decarboxylated to acetyl CoA, and condensed with oxaloacetate, have two potential fates.
These glucose-derived carbons, when incorporated into citrate, may either be oxidized via the Krebs TCA cycle or exported from mitochondria. Once exported, cytosolic citrate is processed by ATP citrate lyase (ACL) to produce cytosolic acetyl CoA and regenerate oxaloacetate (Srere, 1972; Sullivan et al., 1974) . Cytosolic acetyl CoA is the requisite building block for all endogenous synthesis of acyl groups and sterols. We hypothesized that the conversion of glucose to lipid precursors might be required for cell growth. To test this hypothesis, we determined whether cytokines induced the conversion of glucose to lipid in growing cells and evaluated the consequences of ACL inhibition on cell growth, survival, and tumorigenesis.
Results
Cell growth requires ongoing lipid production. New lipid biomass might be derived from the conversion of other macromolecules to lipid (lipogenesis) or from the utilization of pre-existing extracellular lipids. FL5.12 cells are a nontransformed murine hematopoietic cell line reliant on a single cytokine, interleukin-3 (IL-3), for growth, proliferation, survival, and nutrient uptake (McKearn et al., 1985; Nunez et al., 1990; Vander Heiden et al., 2001) . To determine if glucose is utilized to synthesize lipid de novo in growing cells, FL5.12 cells cultured with IL-3 were incubated in the presence of radiolabeled glucose, cellular lipids were extracted, and Glucose is taken up from the extracellular environment and converted to cytosolic pyruvate through glycolysis. Pyruvate is imported into the mitochondrial matrix, where it is decarboxylated to acetyl CoA and condensed with oxaloacetate to form citrate. Citrate has two potential fates: oxidation in the Krebs TCA cycle in the mitochondrion or export to the cytosol. Cytosolic citrate may be cleaved by ACL to form acetyl CoA and regenerate oxaloacetate. Oxaloacetate may be converted to malate by malate dehydrogenase and then reimported to mitochondria. Cytosolic acetyl CoA is the building block for endogenous lipid synthesis, including the production of fatty acids and isopentenyl pyrophosphate. (b) Cells were incubated with 14 C-glucose for 5 h. Cellular lipids were extracted and resolved by thin-layer chromatography. Counts were determined in unfractionated (Total lipid), phospholipid, cholesterol (Chol.), triglyceride (TG), free fatty acid (FFA), and cholesterol ester (Chol. ester) fractions. As a control to ensure the specificity of the measurement for lipid incorporation during the incubation period, radiolabeled glucose was also added to cells immediately prior to extraction. Experiments were conducted in triplicate; data are expressed as the mean7standard deviation. Statistically significant time-dependent incorporation of glucose into lipid was noted for all lipid fractions examined, including free fatty acids (Po0.05) and cholesterol esters (Po0.05). (c, e) Cells were withdrawn from IL-3 overnight and then restimulated for 5 h with 3.5 ng/ml IL-3 concurrently with the addition of C-pyruvate (f), cellular lipids were extracted and lipid counts determined. Experiments were conducted in triplicate; data are expressed as mean7s.d radioactive counts were determined. A significant incorporation of glucose to lipid was observed in these cells (Figure 1b ). Lipid extraction followed by thin-layer chromatography was performed to determine which classes of lipids were generated through de novo lipogenesis. Phospholipid synthesis accounted for the bulk of total lipid synthesis (Figure 1b) . Other classes of lipids synthesized included cholesterol, triglycerides, and, at lower levels, free fatty acids and cholesterol esters.
To determine if lipid synthesis was regulated by IL-3 availability, we measured the rate of glucose-dependent lipid synthesis in cells withdrawn from IL-3 compared to those in which IL-3 availability was restored. The rate of glucose-dependent lipid synthesis was significantly increased by IL-3 stimulation (Figure 1c) . The PI3K/ Akt signaling axis is activated by IL-3 stimulation and plays an important role in regulating glucose metabolism. To assess the significance of the PI3K/Akt pathway for regulating the conversion of glucose to lipid downstream of the IL-3 receptor, cells were stimulated with IL-3 in the presence or absence of the PI3K inhibitor LY294002. Treatment with LY294002 significantly reduced IL-3-stimulated glucose to lipid conversion ( Figure 1c ). To test if Akt signaling was sufficient to stimulate glucose to lipid conversion, cells expressing a constitutively active myristoylated Akt1 transgene (myrAkt) were utilized in the presence of reduced levels of IL-3 stimulation . Compared to vector control cells, Akt-expressing cells displayed an elevated capacity to convert glucose to lipid (Figure 1d ). These data suggest that PI3K/Akt signaling is both necessary and sufficient for promoting IL-3-mediated conversion of glucose to lipid.
Conversion of glucose to lipid requires numerous steps including: glucose uptake, metabolism of glucose to pyruvate by glycolysis, mitochondrial import and decarboxylation of pyruvate to acetyl CoA, condensation of acetyl CoA with oxaloacetate to form citrate, mitochondrial export of citrate, and metabolism of citrate to acetyl CoA ( Figure 1a ). Cytosolic acetyl CoA is the essential building block for endogenous fatty acid and sterol synthesis. IL-3 and the PI3K/Akt signaling pathway are known to activate glucose uptake and glycolysis. To test if glucose to lipid conversion was also regulated downstream of glucose uptake and glycolysis, we incubated cells with radiolabeled pyruvate, the glycolytic end-product, and isolated cellular lipids. The rate of pyruvate incorporation into lipid was significantly increased by IL-3 stimulation ( Figure 1e ). The PI3K inhibitor LY294002 impaired this IL-3-mediated stimulation ( Figure 1e ). Furthermore, expression of activated Akt was sufficient to induce increased incorporation of pyruvate to lipid (Figure 1f ). These data suggest that glucose to lipid conversion is likely regulated at multiple steps, including those downstream of glucose uptake and glycolysis.
A key step in lipid synthesis is catalysed by ACL, which cleaves citrate to generate cytosolic acetyl CoA, the lipogenic building block (Srere, 1972; Sullivan et al., 1974) . ACL is phosphorylated on serine 454 in response to insulin (Pierce et al., 1981 (Pierce et al., , 1989 Yu et al., 1990) . More recently, Akt has been shown to directly phosphorylate ACL on serine 454 and this phosphorylation has been reported to stimulate the enzymatic activity of ACL (Potapova et al., 2000; Berwick et al., 2002) . To test the potential regulation of ACL in response to cytokine signaling, its phosphorylation status was determined. IL-3 signaling led to a dose and time-dependent increase in ACL serine 454 phosphorylation (Figure 2a and b) . LY294002 reduced IL-3-dependent ACL phosphorylation and Akt expression stimulated this phosphorylation event in these cells (Figure 2c and d) .
The regulated conversion of glucose to lipid could contribute to the increase in biomass observed during cytokine-induced cell growth. Therefore, we sought to determine the significance of glucose contribution to de novo lipid synthesis during cell growth by inhibiting ACL. ACL expression was suppressed by the stable transfection of plasmids encoding short hairpin RNA (shRNA) constructs. Two clones expressing an empty shRNA vector (vec 1 and 2) as well as two clones expressing shRNA targeting ACL (ACL 1 and 2) were selected. The shRNA ACL clones displayed reduced ACL expression (Figure 3a) . These knockdown clones possessed decreased ACL activity as measured by a malate dehydrogenase-coupled ACL assay ( Figure 3b ). As anticipated, these clones also demonstrated a reduced ability to metabolize glucose to lipid (Figure 3c ).
Given the decreased conversion of glucose to lipid in these clones, we sought to determine whether decreased expression of ACL impaired cell growth. The ability of the cells to accumulate in culture was tested. The ACL Figure 2 ACL phosphorylation is regulated by IL-3 and PI3K/ Akt signaling. Cells were withdrawn from IL-3 overnight and then restimulated with 3.5 ng/ml IL-3 for 0-30 min (a), for 30 min at 0.01, 0.05, or 0.35 ng/ml IL-3 (b), and for 30 min with 3.5 ng/ml IL-3 in the absence or presence of 20 mM LY294002 (c). Vector control or inducible myrAkt cells were induced with doxycycline for 48 h (d). Cell lysates were resolved by SDS-PAGE and probed for P-ACL S454, ACL, and actin knockdown cells proliferated at a lower rate than controls. For example, after 48 h in culture, the control cells had expanded 8.6 and 8.8 times, respectively. In contrast, the two ACL knockdown clones experienced 4.4-fold and 3.8-fold expansion at this time point (Figure 3d ). This defect in cell proliferation was associated with a delay in specific phases of the cell cycle (Figure 3e ). Fewer shRNA ACL cells were in the S phase and more were in the G1 phase of the cell cycle.
In cells with reduced ACL activity, citrate conversion to cytosolic acetyl CoA is likely impaired. As a consequence, citrate may be preferentially oxidized in mitochondria, leading to increased flux through the Krebs TCA cycle and increased production of substrates for the electron transport chain (Board and Newsholme, 1996) . To test this hypothesis, we compared mitochondrial membrane potential (MMP) between control and ACL knockdown cells. MMP was determined by measuring the fluorescence of cells stained with the potentiometric dye TMRE. Cells expressing ACL shRNA displayed increased MMP as compared to the control cells (Figure 4a ). The specificity of the measurement for MMP was verified by the lack of TMRE signal in the presence of the mitochondrial uncoupling agent CCCP in both control and ACL knockdown cells.
Cells deprived of either glucose or growth factors experience a decline in mitochondrial substrates and a reduction in MMP preceding cell death (Vander Heiden et al., 2001 ). Since cells with reduced ACL activity displayed elevated MMP, presumably due to increased citrate oxidation, we hypothesized that these cells might be relatively resistant to loss of MMP following IL-3 withdrawal. Cells were withdrawn from IL-3, and live cells were analysed for TMRE fluorescence (Figure 4b ). All cells displayed a time-dependent reduction in MMP following IL-3 withdrawal. However, the cells expressing ACL shRNA maintained a higher MMP as compared to control cells at each time point studied.
Previous work has suggested that preventing the loss in MMP following IL-3 withdrawal can delay the onset of cell death (Gottlieb et al., 2003) . Therefore, the kinetics of cell death following IL-3 withdrawal were studied. The shRNA ACL cells displayed a significant delay in the induction of cell death following IL-3 withdrawal (Figure 4c) . At 18 h following IL-3 withdrawal, 20 and 29% of the two control cell lines were viable, whereas 63 and 74% of the ACL 1 and 2 cells remained viable, respectively. This decreased sensitivity of the ACL knockdown cells to cell death following IL-3 withdrawal appeared to be due to protection from apoptosis. ACL knockdown cells were significantly more resistant to the induction of Annexin V expression and caspase-3 cleavage as compared to control cells following IL-3 withdrawal (data not shown).
Following IL-3 withdrawal, cells lose the ability to take up glucose prior to their commitment to cell death (Gonin-Giraud et al., 2002) . Since ACL knockdown cells appeared to favor citrate oxidation by minimizing their glucose-to-lipid flux, their resistance to cell death induced by glucose limitation was assessed. Cells were switched from 10 to 0.02 mM glucose in the presence of IL-3 and their viability was assessed after 48 h. The shRNA ACL cells were significantly protected from cell death induced by glucose limitation as compared to control cells (Figure 4d ).
Given these contrasting effects of ACL knockdown on both inhibiting cell growth and on maintaining cell viability in response to IL-3 and glucose withdrawal, we sought to determine the effect of ACL knockdown on cellular transformation. Expression of an activated form of the proto-oncogene Akt is sufficient to predispose FL5.12 cells to tumorigenesis (Karnauskas et al., 2003) . Cells expressing constitutively active Akt and stably expressing either the shRNA construct targeting ACL or the vector control were generated. As expected, the two independently derived ACL knockdown cell lines expressed reduced levels of ACL and decreased ACL activity as compared to the control cells (Figure 5a and b) . Cells derived from lymph nodes of mice that had developed leukemia were isolated, selected for puromycin resistance, and analysed for expression of ACL. Leukemic shRNA ACL cells still expressed reduced levels of ACL as compared to controls (data not shown). However, the level of knockdown was not as great as that observed in the shRNA ACL cells prior to leukemogenesis, suggesting that the shRNA ACL cells ultimately giving rise to leukemia had been selected in vivo for relatively higher ACL expression than those cells originally administered to the animals.
Discussion
Growing cells face a steep biosynthetic challenge; each time they divide they must double their macromolecular mass. For example, growing cells must continuously duplicate the phospholipids, sphingolipids, cholesterol, and lipid moieties for protein modification that are essential for membrane integrity, permeability, and signal transduction. Such ongoing lipid synthesis could derive its substrates from either lipid salvage or de novo lipogenesis pathways. FL5.12 cells appear capable of lipid salvage insofar as they can bind and internalize LDL lipoprotein particles in a manner regulated by IL-3 availability (Edinger and Thompson, 2002) . However, IL-3-stimulated FL5.12 cells also upregulate glucose metabolism in excess of their bioenergetic demands. We hypothesized that one reason actively growing cells process glucose at such high rates is to ensure that they are never limited for biosynthetic substrates. Therefore, we sought to determine if these cells in fact employed de novo lipogenesis to support their biosynthetic requirements. We found that glucose was converted to lipid in these growing cells and that this process was regulated by IL-3 signaling and mediated by the PI3K/Akt pathway. This conversion was regulated at multiple steps, including glucose uptake, glycolysis, and pyruvate conversion to lipid. ACL is critical for the conversion of glucose to cytosolic acetyl CoA and therefore for glucose-dependent lipogenesis. ACL deficiency in mice results in embryonic lethality, with no viable embryos detectable even at early stages of development (Beigneux et al., 2004) , suggesting that other enzymes potentially capable of supplying cytosolic acetyl CoA, such as acetyl CoA synthetase (Imesch and Rous, 1984) , are unable to functionally complement ACL. By utilizing citrate as a substrate to generate cytosolic acetyl CoA, ACL also serves to divert mitochondrial citrate from oxidation in the Krebs TCA cycle. Thus, the metabolic consequences of ACL knockdown observed in this study included not only a decreased ability to convert glucose to lipid but also an increased mitochondrial membrane potential. In addition, ACL was required to maintain rapid cell proliferation in IL-3-dependent cells, suggesting that glucose-dependent lipogenesis is an important component of cell growth. In contrast, ACL knockdown led to enhanced cell survival upon deprivation of either IL-3 or Figure 5 ACL expression promotes tumorigenesis. myrAktexpressing FL5.12 cell clones were selected to stably express vector or ACL shRNA constructs. Immunoblot (a) and ACL activity (b) are shown for a vector control shRNA clone (vec) and two ACL shRNA expressing clones (ACL 1 and ACL 2); error bars represent s.d. of experiments performed in triplicate. (c) Akt expressing vec or ACL 1 shRNA cells were administered by retro-orbital injection to athymic nu þ /nu þ mice (six mice for vec, five mice for ACL 1) and the animals were monitored by physical examination for lymphadenopathy and hepatosplenomegaly. Mice were killed when visibly ill. P-value (for overall survival time of recipients of shRNA vec versus shRNA ACL 1 cells, Po0.05) was determined by logrank test. (d) In an independent experiment, Akt expressing vec or ACL 2 shRNA cells were administered by retro-orbital injection to athymic nu þ /nu þ mice (nine mice for vec, eight mice for ACL 2) and the animals were monitored by physical examination for lymphadenopathy and hepatosplenomegaly. Mice were killed when visibly ill. P-value (for overall survival time of recipients of shRNA vec versus shRNA ACL 2 cells, Po0.01) was determined by logrank test.
glucose. These findings are consistent with a model in which cells characterized by a primarily oxidative mode of metabolism are relatively quiescent and resistant to death by neglect (Vander Heiden et al., 2001; Bauer et al., 2004) .
Transformed cells autonomously activate growth factor signaling pathways. This chronic stimulation often leads to high rates of glucose uptake (Warburg, 1956; Dang and Semenza, 1999) . The PI3K/Akt pathway is autonomously upregulated in many cancer cells and stimulates glucose metabolism in excess of bioenergetic demand (Elstrom et al., 2004) . ACL itself is an Akt substrate (Berwick et al., 2002) . Therefore, we hypothesized that Akt-transformed cells might be dependent on ACL as a growth promoter through its role in de novo lipogenesis. Despite the ability of ACL knockdown to render cells more resistant to cell death, Akt-activated cells with ACL knockdown developed into leukemia at a reduced rate and frequency. Thus, ACL appears to contribute to Akt-mediated tumorigenesis.
The metabolic reprogramming of cancer cells raises the question of whether a therapeutic window exists for targeting key metabolic steps. Cancer cells may become dependent on their unique form of metabolism and be especially susceptible to its disruption. For example, Akt-expressing cancer cells are much more sensitive to glucose withdrawal-induced cell death than cells not expressing Akt (Elstrom et al., 2004) . Various steps in lipid biosynthesis have been considered as targets for the treatment of cancer. Fatty acid synthase has been reported to be highly expressed in a number of cancer cells, and inhibition of fatty acid synthase has shown selectivity for causing cancer cell death in vitro and in vivo (Kuhajda et al., 1994; Alli et al., 2005) . Blockade of HMG CoA reductase also has the ability to inhibit cancer cell growth, and the clinical utilization of statins has been associated with a decreased incidence of cancer in some retrospective epidemiologic studies (Sumi et al., 1992; Dimitroulakos et al., 1999; Boudreau et al., 2004; Graaf et al., 2004) . Furthermore, inhibitors of protein farnesylation have demonstrated promise as anticancer agents (Russo et al., 2004) . Since ACL is the first committed step in channeling glucose-derived metabolites towards a lipid biosynthetic fate and since oncogenic PI3K/Akt signaling can positively regulate ACL, ACL is a particularly appealing target for the treatment of malignancy. ACL activity supports both membrane biosynthesis and the generation of lipid modifications of signaling proteins through the endogenous production of acyl groups and isopentenyl pyrophosphate. Future experiments will help to evaluate the selectivity and utility of the strategy of inhibiting ACL for treating cancer.
Materials and methods
Cell culture and flow cytometry FL5.12 cells were cultured in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen), 10 mM HEPES (Invitrogen), 50 U/ml penicillin, 50 mg/ml streptomycin (Invitrogen), 50 mM 2-mercaptoethanol (Sigma), and recombinant IL-3 at 0.35 ng/ml (R&D Systems). For experiments with overnight IL-3 withdrawal followed by restimulation, cells expressing Bcl-x L were utilized to prevent the induction of apoptosis . For experiments with myrAkt cells, cells were cultured as described (Elstrom et al., 2004) . These cells were cultured in reduced levels of IL-3, so that basal IL-3-stimulated glucose metabolism was diminished, but in which sufficient IL-3 was present to prevent the induction of apoptosis in control cells. For glucose limitation experiments, cells were cultured in RPMI 1640 (Invitrogen) at a final concentration of 10 or 0.02 mM glucose, supplemented with 10% dialysed fetal bovine serum (Invitrogen), 10 mM HEPES (Invitrogen), 50 U/ml penicillin, 50 mg/ml streptomycin (Invitrogen), 50 mM 2-mercaptoethanol (Sigma), and recombinant IL-3 at 0.35 ng/ml (R&D Systems). Cells were counted using a Coulter Z2 particle analyser. To assess cell viability, cells were pelleted, resuspended in PBS with 2 mg/ml propidium iodide (Molecular Probes) and analysed by flow cytometry. For cell cycle analysis, cells were pulsed for 30 min with 10 mM BrdU (Sigma). Cells were fixed, stained with anti-BrdU mAb (PharMingen) and propidium iodide, and analysed by flow cytometry. For mitochondrial membrane potential analysis, cells were stained with 20 nM tetramethyl rhodamine ethyl ester (TMRE; Molecular Probes) in the presence or absence of 50 mM CCCP (Sigma) for 30 min at 371C followed by flow cytometry.
Immunoblot RIPA whole-cell lysates were standardized for protein content and resolved by SDS-PAGE. Nitrocellulose blots were probed with antibodies against phospho-ACL serine 454 (P-ACL S454; Cell Signaling) and actin (Sigma A5441), and a polyclonal rabbit serum generated against the ACL peptide IGHYLDQKRLKQGLYRH. Cells were pretreated with 20 mM LY294002 (Cell Signaling) for 30 min prior to IL-3 stimulation.
shRNA
The pKD vector used to express short hairpins for RNAi was derived from pBabe-Puro or pBabe-GFP by deleting a portion of the 3 0 LTR. The human U6 RNA polymerase III promoter (À265 to À1) was PCR amplified from HeLa genomic DNA and TA cloned into pEF6/V5-HIS generating pEF6-hU6. To generate shRNA, a PCR-based strategy was employed using pEF6-hU6 as a template and primers containing the DNA hairpin sequence as previously described (Paddison and Hannon, 2002; Edinger et al., 2003) . The resultant PCR product (330 bp) was TOPO-TA cloned into pEF6/V5-HIS, hairpin sequence in the correct orientation excised with EcoRV and BamHI and ligated into the SnaBI and BamHI sites of pKD. The ACL hairpin sequence (sense) is 5 0 GGC ATG TCT AAT GAA CTC AA 3 0 . Stable cell clones were selected by cell sorting (for pBabe-GFP-based vector) or puromycin resistance plus limiting dilution (for pBabe-Puro-based vector).
Lipid synthesis
Cells were resuspended in fresh media at 5 million cells/ml in triplicate. In all, 2 mCi/ml D- [6- 14 C]glucose (final concentration 36 mM) or 5mCi/ml [2-
14 C]pyruvate (final concentration 227 mM) was added and cells were incubated at 371 for 5 h. Cells were pelleted and washed three times in PBS. Cellular lipids were extracted by a modification of the Bligh Dyer protocol (Bligh and Dyer, 1959) . Briefly, cells were disrupted by sonication or lysis in a 0.5% Triton X-100 solution in 400 ml. Sequentially added were 2 ml MeOH, 1 ml chloroform, and 1 ml dH 2 O. Samples were centrifuged at 1000 r.p.m. for 15 min, the chloroform phase recovered, samples dried under N 2 , resuspended in 100 ml chloroform, and counted in ScintiVerse (Fisher) on a Beckman LS 6500 scintillation counter. For TLC, the chloroform phase resuspended in 100 ml chloroform was spotted at the origin of the plate. The plate was composed of glass microfiber chromatography paper impregnated with silicic acid (Varian) and heat inactivated at 901C for 1 h prior to use. The solvent system was hexane : -diethyl ether : acetic acid at a ratio of 170 : 30 : 1. Plate was run for 9 min, dried, and stained with iodine to visualize standards. Bands were excised and samples counted in ScintiVerse (Fisher) on a Beckman LS 6500 scintillation counter.
ACL assay
ACL activity was measured via the malate dehydrogenasecoupled method (Srere, 1959) . RIPA whole-cell lysates were added at a 1 : 19 ratio to the reaction mixture containing 100 mM Tris-HCl (pH 8.7), 20 mM potassium citrate, 10 mM MgCl 2 , 10 mM DTT, 0.5 U/ml malate dehydrogenase, 0.33 mM CoASH, 0.14 mM NADH, and 5 mM ATP (all from Sigma). Change in absorbance at 340 nm was read every 15 s over 35 min in a SpectraMax 190 spectrophotometer. Change in absorbance in the absence of exogenous ATP was subtracted from change in the presence of ATP and was normalized to protein concentration to determine the specific ACL activity.
Tumorigenesis
Parental FL5.12 cell lines constitutively expressing myristoylated Akt1 have been described previously (Fox et al., 2003) .
For leukemogenesis studies, 5 Â 10 7 cells were administered by retro-orbital injection to 8-10-week-old female athymic nu þ / nu þ mice (Charles River) and mice were monitored by physical examination for lymphadenopathy and hepatosplenomegaly. Mice were killed when visibly ill. Lymph nodes were isolated from affected animals and leukemic cell lines were derived by culture in the presence of puromycin.
Statistical analysis
For the leukemogenesis experiments, overall survival (OS) was calculated from the time of cell administration to the time of death. Analysis of OS was performed using the Kaplan and Meier method, with differences between groups compared by the log-rank test. For the lipid synthesis experiments, radioactivity counts for lipid incorporation into cholesterol esters and free fatty acids were compared with background counts using the paired t-test for matched samples, assuming a normal underlying distribution of radiation counts. All P-values were two-sided. Statistical analysis was carried out using the STATA program (STATA v.8, College Station, TX, USA: STATA Corporation, 2003) .
